[go: up one dir, main page]

AU2001282706A1 - HIV peptides from conserved in gag p17 and 924 and their application in E.G. vaccines - Google Patents

HIV peptides from conserved in gag p17 and 924 and their application in E.G. vaccines

Info

Publication number
AU2001282706A1
AU2001282706A1 AU2001282706A AU2001282706A AU2001282706A1 AU 2001282706 A1 AU2001282706 A1 AU 2001282706A1 AU 2001282706 A AU2001282706 A AU 2001282706A AU 2001282706 A AU2001282706 A AU 2001282706A AU 2001282706 A1 AU2001282706 A1 AU 2001282706A1
Authority
AU
Australia
Prior art keywords
xaa
information
leu
gly
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2001282706A
Other versions
AU2001282706B2 (en
Inventor
Birger Sorensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bionor Immuno AS
Original Assignee
Bionor Immuno AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NO20004413A external-priority patent/NO314588B1/en
Application filed by Bionor Immuno AS filed Critical Bionor Immuno AS
Publication of AU2001282706A1 publication Critical patent/AU2001282706A1/en
Application granted granted Critical
Publication of AU2001282706B2 publication Critical patent/AU2001282706B2/en
Priority to AU2007202739A priority Critical patent/AU2007202739B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Description

Title : HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
The present invention relates to novel peptides based on conserved regions of HIV gag p17 and p24, antigens in free or carrier-bound form comprising at least one of the said peptides, vaccine compositions containing at least one of the antigens, immunoassay kits and a method of detecting antibodies, induced by human immunodeficiency virus (HIV) or HIV-specific peptides, using such antigens.
BACKGROUND
There is an urgent need to control the global epidemic of HIV infection and the development of a vaccine against HIV is one of the major objectives in AIDS research. In general vaccines should activate antigen presenting cells, overcome genetic restriction in T-cell responses and generate T- and B-memory cells. The variability of the viral population poses a further difficulty in obtaining an effective HIV vaccine. A break through in the ongoing attempts to develop a vaccine against AIDS has so far not been reported. It is now generally accepted that an induction of antigen-specific humoral and cell-mediated immunity is crucial for a development of an effective prophylactic and therapeutic vaccine. All three arms of the immune system including neutralizing antibodies; CD8+CTL and T-helper-1 (TH1) cells might be required for protective immunity to HIV. It is" known that CTL can clear other viral infections (Ada, Immunol. Cell Biol., 72:447-454, 1994) and that CTL can lyse infected targets early in infection before viral progeny can be produced and released by cell lysis, Ada et al., supra. The focus has been on selection of antigens as well as on design and evaluation of different adjuvances. The antigens used in different in vitro and in vivo studies have been all from crude proteins to various synthetic peptides from several of the HIV proteins. A large number of studies have been done on the V3 loop of gp120. Induction of both B- and T-cell responses have been observed, however, it has been reported from an in vitro study that a peptide from the conserved region of gp41 have indicated infection enhancement ( Bell S.J., et al., Clin. Exp. Immunol., 87 (1) : 37-45, ( January 1992).
Naturally occurring HIV sequences in vaccine candidates are not capable of stimulating a stable immune response due to the viruses inherent ability to hide by changing the appearance of the epitopes presented on the cell surface of infected cells. The immune system is fooled to believe that a particular amino acid sequence is relevant when in fact the amino acids of importance is hidden.
A recent study of titers of antibodies against the gag p24 protein, has shown that slow progression towards development of AIDS is associated with high titers, while fast progression towards development of AIDS is associated with low titers. It is shown that persons with low p24 antibody titer develop significantly faster AIDS than persons with high p24 antibody titers ( Zwart G., et al. Virology, 201 , p. 285-93, June 1994), indicating that gag and p24 in particular can play a key role to control the development of AIDS.
New HIV p24 peptides are described in WO91/13360, wherein the peptides are used in a method of discriminating between a false and true diagnosed HIV-positive serum sample.
Johnson R.P., et al., The Journal of Immunology, Vol.147, p.1512-1521, No.5, September 1 , 1991 describe an analysis of the fine specificity of gag-specific CTL- responses in three HIV-1 seropositive individuals, the gag-specific CTL-responses were found to be mediated by CD3+ CD8+ lymphocytes which are HLA class I restricted. Goulder P.J.R. et.al., Journal of Virology, Vol. 74, p.5679-5690, No 12, June 2000 has studied CTL response from different parts of p17 and p24 of HIV in different populations. The findings show that certain immunodominant regions exist, however, minor differences in amino acid composition can cause large differences in response.
EP-A-0 356 007 discloses antigenic determinants, in particular it relates to synthetic polypeptide sequences which are related to proteins present in the HIV-1 and which can be used as a basis for a potential vaccine against AIDS.
Rosenberg E.S. et al., Science, Vol.278, 21 November 1997, p.1447-1450 describe that virus specific CD4+ T helper lymphocytes are critical to the maintenance of effective immunity in a number of chronic viral infections, but are characteristically undetectable in chronic human immunodeficiency virus-type 1 (HIV-1) infection. HIV-1 -specific proliferative responses to p24 were inversely related to viral load. They conclude that the HIV-1 -specific helper cells are likely to be important in immunotherapeutic interventions and vaccine development. EP 0 230 222, EP 0 270 114, DE 37 11 016 and GB 2 188 639 all in the name of F. Hoffmann-La Roche & Co. Aktiengesellschaft concern recombinant expression and purification of an HTLVIII Gag/Env gene protein or fusion proteins. The proteins consisting of native sequences can be purified to homogeneity and used as a basis for diagnostic tests for detection of antibodies against viruses associated with AIDS. The gag/env protein may also be formulated for use as a vaccine for protection against AIDS through prophylactic immunization.
From a diagnostic and therapeutic point of view, the major problems with using p24 as part of an assay or therapy is associated with the high number of epitopes on p24 which stimulates production of a large number of antibodies with poor specificity, which through repeated boostering on potential mutated sequences can create autoantibodies (Autoantibodies to the alfa/beta T-cell receptors in HIV infection; dysregulation and mimicry. Lake D.F., et al., Proc. Natl. Acad. Sci. USA, (23) : 10849-53, Nov. 8 1994). Further, it is reported that the p24 antibody titer does not reach the same high levels as for the envelope proteins (gp120 and gp41). Normally antibodies to p24 are developed in the very early phase of the infection, but the titer is fairly quickly stabilized after the initial infection period. Later the p24 titer is gradually decreasing while the opposite happens with gp160. These findings can also be seen in relation to recent reports stating that cytotoxic T-cell activity is antagonized by naturally occurring HIV-1 gag variants (Klenerman P., et al., Nature, 2:369 (6479), p. 355, 2 June 1994). This can be one of the reasons why a rapid stabilization of the p24 titer is seen and why it later starts to decrease. Based on the above background data, we decided to investigate the possibility of designing novel synthetic peptides which can mimic the p17 and p24 epitopes without antagonizing the cytotoxic T-cell activity, in order to meet the need for an effective prophylactic and therapeutic vaccine.
The sequence of p17 identified as a possible template for development of peptides that can elicit CTL and antibody response is published by Korber B., et al., Human Retroviruses and AIDS 1999 Eds.Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM. The identified amino acid sequence is located between the amino acids 33 and 53, confer table 1 : Table 1
AA AA no. sequence Naturally occurring AA's
34 I L V M
35 I V
36 W
37 A
38 S N R
39 R S
40 E
41 L M
42 E D K G Q
43 R K G N
44 F S Y
45 A T S
46 V L l C
47 N D S
48 P R s T
49 G S A D N Q
50 L F
51 L M
52 E G D
53 T S A
The one letter as well as the three letter codes defining the amino acids in the sequences given throughout this specification are in accordance with International standards and given in textbooks, for instance Lehninger A.L., «Principles of
Biochemistry», Worth Publishers Inc., New York, 1982. The amino acids given to the right of the second column represent the natural variation of the sequence. A change in the overall charge of the epitope by modification of amino acids can involve a significant improvement of the immunogenicity. The modifications involve a probable conformation change from the original helical to a sheet structure, exposing the epitope to the immune system in a different manner and expectingly to a greater extent.
To further increase the number of T-cell epitopes and reduce the probability for development of escape mutants within the gag protein three additional peptide sequences from p24 were based on the following three sequences from residues 133- 158, 178-199 and 233-251 , respectively published in Human Retroviruses and AIDS 1999; A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Eds.Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, confer tables 2-4 :
Table 2
AA
AA no. sequence Naturally occurring AA's at each AA position
133 P
134 I V L
135 V M A I
136 Q S T V
137 N D T
138 I A L M
139 Q E K G
140 G
141 Q I
142 M P A
143 V I A T R
144 H
145 Q H
146 A S V N P
147 I L M V
148 S T
149 P A
150 R
151 T
152 L S
153 N F
154 A
155 W
156 V
157 K
158 V A C Table 3
AA
AA no. sequence Naturally o ccuπ
178 G
179 A
180 T A I V
181 P S
182 Q H G Y
183 D
184 L l V
185 N Y
186 T M L
187 M
188 L
189 N S T
190 T I V A
191 V I
192 G
193 G D
194 H
195 Q
196 A G
197 A
198 M L
199 Q E H and
Table 4
Naturally occurring AA's at each AA
AA no. AA sequence position
233 G
234 S A
235 D
236 I
237 A
238 G Table 4 cont.
239 T A s
240 T S
241 s T
242 T N s
243 L P V Q
244 Q A H
245 E
246 Q H
247 I L V M
248 G A Q T N R H
249 W
250 M T
251 T s
Several modified peptides have been synthesized in order to determine unique sequences which are both specific and sensitive towards HIV-1.
DESCRIPTION OF THE INVENTION
The peptides according to the invention are originating from the four different conserved areas of the HIV-1 gag protein p17 and p24 which are described above, having the properties of maintaining the uniqueness of the HIV-1 -epitope. Further the new peptides according to the invention possess no recognized cytotoxic T lymphocyte (CTL) antagonistic effect and shall have at least one potential CTL epitope.
The peptides, according to the invention, which have met the above criteria are selected from the following groups ;
Xaai Xaa2Xaa3Xaa4 Xaa5 Xaa6 Xaa7Gln Leu Gin Xaan Xaa-ι2 Xaa-ι3 Xaa-|4Xaa-i5 Xaa-iβ Xaa-]7 Xaa-isXaa-ig Xaa20 Xaa2ι (SEQ ID NO : 1)
wherein the amino acids of the chain could have the following meanings ; Xaa in position 1 of the peptide derivate is His, Lys or Arg, Xaa in position 2 is He, Leu, Val or Met, Xaa n position 3 is lie or Val, Xaa n position 4 is Trp or Tyr, Xaa n position 5 is Ala or Leu, Xaa n position 6 is Ser, Thr, Arg or Asn, Xaa n position 7 is Arg or Ser, Xaa n position 11 s Arg, Lys, Gly or Asn, Xaa n position 12 s Phe, Ser or Tyr Xaa n position 13 s Ala, Thr or Ser Xaa n position 14 s Val, Leu, lie or Cys, Xaa n position 15 s Asn, Asp or Ser, Xaa n position 16 s Pro, Arg or Ser, Xaa n position 17 s Gly, Ser, Ala, Asp or Asn Xaa n position 18 s Leu or Phe, Xaa n position 19 s Leu or Met, Xaa n position 20 s Glu, Gly, Asp or lie, Xaa n position 21 s Thr, Ser or Ala the peptide comprises at least six consecutive amino acids of the sequence of SEQ ID NO : 1 ,
Xaai Xaa2 Xaa3 Xaa4 Xaa5 Xaaβ Xaa7 Gly Xaa9 Leu Val -Z- Tyr Xaaι3 Xaaι4 Xaa15 Xaa16 Xaaι7Xaai8 Xaa-ι9 Xaa20 Xaa2ι Ala Xaa23 Xaa24 Xaa25 Xaa26 (SEQ ID NO : 4)
wherein the amino acids of the chain have the following meaning;
Xaa in position 1 is Pro, Tyr or Phe Xaa in position 2 is lie, Val or Leu,
Xaa in position 3 is He, Ala, Val, Met or Leu
Xaa in position 4 is Gin, Ser, Thr or Val
Xaa in position 5 is Asn, Asp or Thr
Xaa in position 6 is lie, Ala, Leu or Met Xaa in position 7 is Gin, Glu Lys or Gly
Xaa in position 9 is Gin or lie
Xaa in position 13 is omitted
Xaa in position 14 is Ala, Ser, Asn, Val or Pro
Xaa in position 15 is lie, Leu, Met or Val, Xaa in position 16 is Ser or Thr Xaa in position 17 s Pro or Ala, Xaa in position 18 s Arg or Lys, Xaa in position 19 s Thr or Ser Xaa in position 20 s Leu or Ser Xaa in position 21 s Asn, Phe or Val, Xaa in position 23 s Trp, Tyr, Gly or none Xaa in position 24 s Val, Leu, Gly or none Xaa in position 25 s Lys, Arg, Gly or none Xaa in position 26 is Val, Ala, Cys, Gly or none wherein the sequence of SEQ ID NO : 4 comprises at least six consecutive amino acids and -Z- is optional and have the meaning PEG, modified PEG and/or [Gly]n, wherein n = 1 , 2 or 3,
Xaai Ala Xaa3 Xaa4Xaa5 Ala Xaa7 Xaa8 Xaa9 Leu Leu Xaa-|2 Xaa-|3 Xaa14-Z- Xaaι5 Xaai6 His Gin Xaai9 Ala Xaa2ι Xaa22 (SEQ ID NO : 9)
wherein Xaa in position 1 is Tyr, Trp, Phe or Gly
Xaa in position 3 is Thr, Ala, Val, He or Leu
Xaa in position 4 is Pro or Ser
Xaa in position 5 is Gin, His, Gly, Thr, Ser or Tyr
Xaa in position 7 is Leu, He or Val
Xaa in position 8 is Asn or Tyr
Xaa in position 9 is Thr, Met, Leu or Ala
Xaa in position 12 s Ser, Thr or Asn Xaa in position 13 s Thr, He, Val or Ala Xaa in position 14 s Val or He Xaa in position 15 s Gly or none Xaa in position 16 s Gly or none Xaa in position 19 s Ala or Gly Xaa in position 21 s Met, Leu, Cys or none Xaa in position 22 s Gin, Glu, His, Gly or none wherein the sequence of SEQ ID NO : 9 consists of at least six consecutive amino acids and the linker -Z- is optional and have the meaning PEG, modified PEG and/or [Glyjn, wherein n = 1 , 2 or 3, Xaai Xaa2 Ala Leu Ala Gly Xaa7Xaas Xaa9 Leu Xaa-n Xaa-ι2 Xaaι3 Xaa-ι4Xaa-|5Xaai6 Xaaι7 Xaaia Xaaι9Xaa2o Xaa2ι (SEQ ID NO : 15)
wherein the Xaa in position 1 is Trp or Tyr
Xaa in positi on 2 is Ser or Ala Xaa in positi on 7 is Thr, Ala or Ser Xaa in positi on 8 is Ser or Thr Xaa in positi on 9 is Ser or Thr Xaa in posit on 11 is Leu, Pro, Val or Gin Xaa in positi on 12 is Gin, Ala or His Xaa in positi on 13 is Glu or Gly Xaa in positi on 14 is Gin or His Xaa in posit on 15 is lie, Leu, Val or Met Xaa in posit on 16 is Gly, Ala, Gin, Thr, Asn, Arg, His or lie Xaa in posit on 17 is Trp or Tyr Xaa in posit on 18 is Thr, Met, Leu or lie Xaa in posit on 19 is Thr or Ser Xaa in posit on 20 is Cys, Gly or none Xaa in posit on 21 is Gly or none wherein the sequence of SEQ ID NO : 15 consists of at least six consecutive amino acids, the terminal ends of the sequences may be free carboxyl- or amino groups, amides, acyls, acetyls or salts thereof, two or more of the Cys residues may form part of an interchain disulphide binding, a -S- (CH2)P-S- or a - (CH2)p-bridge wherein p = 1-8, optionally intervened by one or more hetero atoms such as O, N or S and/or the said peptide sequences are immobilized to a solid support.
The new peptide sequences have the potential to serve as a good antigen wherein the antigen comprises at least one peptide selected from the group of sequences of SEQ ID NO : 1 , SEQ ID NO : 4, SEQ ID NO : 9 or SEQ ID NO : 15 . The antigenicity may be adapted through adjusting the ratio or concentration of different peptides or size of the peptides by for instance dimerization or polymerization and/or immobilization to a solid phase. The antigen comprises two or more polypeptide sequences, according to the invention, which are either linked by a bridge for instance a disulphide bridge between the Cys residues of the chains or bridges like Cι-C8 alkylen possibly intervened by one or more heteroatoms like O, S, or N or preferably they are unlinked. The chains may be immobilized to a solid phase in monomeric, dimeric or oligomeric forms. Further amino acids may be added to the ends in order to achieve an «arm» to facilitate immobilization.
PEG is polyethylene glycol (HO(CH2CH2θ)mH and can be part of the linker -Z-, optionally PEG is modified by a dicarboxylic acid (HO(CH2CH2O)mCO(CH2)0COOH) or a terminal carboxylic group (HO(CH2CH20)m-ιCH2COOH) where m= 1-10 and o=2-6, prior to linking.
The linker -Z- can either consist of PEG, modified PEG, or a combination thereof and/or one or more Gly residues combined. Alternatively the linker -Z- can consist of a Gly- bridge [Gly]n where n=1 , 2 or 3.
All amino acids in the peptides of the invention can be in both D- or L-form, although the naturally occurring L- form is preferred.
The C- and N-terminal ends of the peptide sequences could deviate from the natural sequences by modification of the terminal NH2-group and/or COOH-group, they may for instance be acylated, acetylated, amidated or modified to provide a binding site for a carrier or another molecule.
The peptides according to the invention are consisting of at least 6 amino acids, preferably between 10 and 30 amino acids. They are covering all natural variation of amino acids in the identified positions.
The polypeptide antigen according to the invention is either in a free or in a carrier- bound form. The carrier or solid phase to which the peptide is optionally bound can be selected from a vide variety of known carriers. It should be selected with regard to the intended use of the immobilized polypeptide as a diagnostic antigen or as an immunizing component in a vaccine.
Examples of carriers that can be used for e.g. diagnostic purposes are magnetic beads or latex of co-polymers such as styrene-divinyl benzene, hydroxylated styrene-divinyl benzene, polystyrene, carboxylated polystyrene, beads of carbon black, non-activated or polystyrene or polyvinyl chloride activated glass, epoxy-activated porous magnetic glass , gelatine or polysaccharide particles or other protein particles, red blood cells, mono or polyclonal antibodies or fab fragments of such antibodies.
According to a further embodiment of the present invention, the antigens may form part of a vaccine possibly combined with carriers, adjuvants or combined with other immunostimulating elements such as canarypox virus carrying the envgeπe. Examples of carriers and/or adjuvants for vaccine purposes are other proteins such as human or bovine serum albumin and keyhole limpet haemocyanin and fatty acids.
Immunostimulatory materials may be divided into three groups; adjuvants, carriers for antigens and vehicles. Examples of adjuvants include aluminum hydroxyd, aluminum salts, saponin, muramyl di and tripeptides, monophosphoryl lipid A, palmitic acid, B. ertussis and various cytokines including the Th1 cytokine IL-12 and IL-1. A number of protein toxins can be used to carry passenger proteins across cellular membranes into the cytosol, which are useful in developing CTL vaccines. Carriers include bacterial toxoids such as inactivated tetanus and cholera toxins, genetically detoxified bacterial toxins such as heat labile enterotoxin from E.coli, fatty acids, live vectors such as polio chimeras and hybrid proteins that form particulates for example yeast retrotransposon hybrid TY particles and HBcAg particles. Vehicles which are frequently occurring components in modern vaccines are consisting of mineral oil emulsion, Freunds complete and incomplete adjuvant, vegetable oil emulsions, nonionic block co-polymer surfactants, squalene or squalane, lipopeptides, liposomes and biodegradable microspheres. Two recent adjuvants which possess significant potential for the development of new vaccines include an oil-in- water microemulsion (MF59) and polymeric microparticles. Any substance that can enhance the immunogenicity of the antigen may be used and several further alternatives of carriers or adjuvants are given in the US or European Pharmacopoeia.
A suitable formulation of the antigen for immunostimulatory uses may also comprise interferons such as INF-γ, antiviral chemokines or haematopoietic growth factors such as granulocyte macrophage growth (colony stimulating) factor.
Another approach in order to enhance the stimulation and absorption in for instance the intestine is to administer the peptides of the invention, with small peptides such as di, tri or tetrapeptides. These peptides can be administered in addition to or in combination with the peptides of the invention. Preferably the peptides are administered together with the tripeptide YGG, consisting of amino acids in the D- or L-forms, preferably in the D-form. Recent approaches to non-parenteral delivery of vaccines, for instance via mucosa include; gene fusion technology to create non-toxic derivatives of mucosal adjuvants, genetically inactivated antigens with a deletion in an essential gene, co-expression of an antigen and a specific cytokine that is important in the modulation and control of a mucosal immune response, and genetic material itself that would allow DNA or RNA uptake and its endogenous expression in the host cells.
One approach for developing durable responses where cell-mediated immunity is required, is to vaccinate with plasmid DNA encoding one or more specific antigen(s).
In order to protect against HIV infection, vaccines should induce both mucosal and systemic immune responses and could be administered by any convenient route, parenterally or non-parenterally, such as subcutanously, intracutanously, intravenously, intramuscularly, perorally, mucosally or intranasally for example.
In a preferred embodiment of the vaccine according to the present invention it comprises antigens containing at least one of the peptides selected from the groups of SEQ ID NO : 1, 4, 9 and 15, more preferred different peptides occur in equal amounts.
In a further preferred embodiment the vaccine composition contains the antigens ;
RLIYATRQLQRFAVNPGLLIT-NH2 (SEQ ID NO : 3)
FILQN IEGQLVGGGYAISPRTLVAGGGG (SEQ ID NO : 6)
YAIPQALNTLLNTVGGHQAA-NH2(SEQIDNO: 11)
and
WSALAGTTSLLQGQLGWIT-NH2 (SEQ ID NO : 14) The sequences contribute with CTL-epitopes and can activate the cellular immune system. The amino acid changes implemented within the frame of the CTL-epitopes are designed to achieve enhanced binding. Other amino acid changes have been conducted in order to facilitate the synthesis of the peptide and/or to increase the solubility of the peptide.
A method for detecting antibodies, induced by HIV-1 or HIV-1 specific peptides or proteins, in a sample of body fluid using the present antigens is a further embodiment of the invention. Also immunoassay kit designed for this detection and antibodies capable of selectively reacting with the said antigens are encompassed by the present invention.
DESCRIPTION OF THE PREPARATION OF THE PEPTIDES
The peptides of the invention can be produced by any known method of producing a linear amino acid sequence, such as recombinant DNA techniques. A nucleic acid sequence which encodes a peptide of the invention or a multimer of the said peptides, is introduced into an expression vector. Suitable expression vectors are for instance plasmids, cosmids, viruses and YAC (yeast artificial chromosome) which comprise necessary control regions for replication and expression. The expression vector may be stimulated to expression in a host cell. Suitable host cells are for example bacteria, yeast cells and mammalian cells. Such techniques are well known in the art and described for instance by Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1989. Other well-known techniques are degradation or synthesis by coupling of one amino acid residue to the next one in liquid phase or preferably on a solid phase (resin) for instance by the so- called Merrifield synthesis. See for instance Barany and Merrifield in the Peptides, Analysis, Synthesis, Biology, Vol.2, E. Gross and Meinhofer, Ed. (Acad. Press, N.Y., 1980), Kneib-Coronier and Mullen Int. J. Peptide Protein Res., 30, p.705-739 (1987) and Fields and Noble Int.J. Peptide Protein Res., 35, p.161-214 (1990).
In case a linked or cyclic peptide is desired, the amino acid sequence is subjected to a chemical oxidation step in order to cyclize or link the two cysteine residues between two peptide sequences, when the appropriate linear amino acid sequences are synthesized, see Akaji et al., Tetrahedron Letter, 33, 8, p.1073-1076, 1992. GENERAL DESCRIPTION OF SYNTHESIS
All peptide derivatives prepared in the Examples given below were synthesized on a Milligen 9050 Peptide Synthesizer using a standard program. The resin used was Tenta Gel P RAM with a theoretical loading of 0,20 meq/g (RAPP POLYMERE GmbH, Tubingen). The final product of the synthesis was dried in vacuo overnight. The peptide was then cleaved from the resin by treatment with 90% trifluoroacetic acid in the presence of ethane dithiol (5%) and water (5%) as scavengers (1 ,5 hours at RT). Then the resin was filtered and washed on filter with additional trifluoroacetic acid (100%) (2 x 20 ml). The combined filtrates were evaporated in vacuo (water bath at RT) and the residue was triturated with ethyl ether (200 ml) and the precipitated product filtered off. The solid was promptly dissolved on filter with glacial acetic acid (100 ml) and added to 1 ,5 I of 20% acetic acid in methanol and treated with 0,1 M solution of iodine in methanol until a faint brown colour remained. Then Dowex 1 x 8 ion exchange in acetate form (15g) (Bio-Rad, Richmond, CA) was added and the mixture filtered. The filtrate was evaporated and the residue freeze-dried from acetic acid. The product was then purified by reversed phase liquid chromatography on a column filled with Kromasil® 100 - 5 C8 (EKA Nobel, Surte, Sweden) in a suitable system containing acetonitrile in 0,1 % trifluoroacetic acid water solution. The samples collected from the column were analyzed by analytical high performance liquid chromatography (HPLC) (Beckman System Gold, USA) equipped with a Kromasil® 100 - 5 C8 Column (EKA Nobel, Surte, Sweden). Fractions containing pure substance were pooled, the solvent was evaporated and the product freeze-dried from acetic acid. The final HPLC analysis was performed on final product, and the structure of the peptide was confirmed by amino acid analysis and mass spectrometry (LDI-MS).
All amino acids used during the synthesis were L-amino acids and they were protected with a fluorenylmethoxy-carbonyl group at the α-amino function. The side chains were protected as follows :
Cys (Trt), Gln(Trt), Glu(OtBu), Thr(tBu).
The abbreviations, within the brackets are : Trt = triphenylmethyl t-Bu = tert. Butyl OtBu = tert. Butylester The amino acid derivatives was supplied by Bachem AG, Switzerland.
EXAMPLE 1
Preparation ofHLIYLTRQLQRFALNPGLLIT-NH2 (SEQ ID NO : 2). The peptide is synthesized in amide form, from corresponding starting materials according to the general description of synthesis. The purity is determined by HPLC analysis and the structure is confirmed by amino acid analysis and mass spectrometry (LDI-MS).
EXAMPLE 2
Preparation of RLIYATRQLQRFAVNPGLLI T-NH2 (SEQ ID NO : 3). The peptide was synthesized in amide form, from corresponding starting materials according to the general description of synthesis. The purity was determined by HPLC analysis and the structure was confirmed by amino acid analysis and mass spectrometry (LDI-MS).
Purity (HPLC) : more than 97% (single impurities less than 1%) Molecular weight (free base) : 2442.9
EXAMPLE 3 Preparation ofYILQNIEGQLVGGGYAISPRTLVAYLRG-NH2
(SEQ ID NO : 5). The peptide is synthesized in amide form, from the corresponding starting materials according to the general description of synthesis. The purity is determined by HPLC analysis and the structure is confirmed by amino acid analysis and mass spectrometry (LDI-MS).
EXAMPLE 4
Preparation ofFILQNIEGQLVGGGYAISPRTLVAGGGG (SEQ ID NO : 6). The peptide was synthesized from the corresponding starting materials according to the general description of synthesis. The purity was determined by HPLC analysis and the structure was confirmed by amino acid analysis and mass spectrometry (LDI-MS). Purity (HPLC) : more than 94 % Molecular weight (free base) : 2745 Molecular formula : Ci23Hι98θ37N34 EXAMPLE 5- REFERENCE EXAMPLE
Preparation of a nativ p24 sequence PIVQNIEGQMVHQAISPRTLNAWV K V (SEQ ID NO : 7). The peptide was synthesized from the corresponding starting materials according to the general description of synthesis. The purity was determined by HPLC analysis and the structure was confirmed by amino acid analysis and mass spectrometry (LDI-MS). Purity (HPLC) : approx.85 % Molecular weight (free base) : 2929 Molecular formula : Ci3iH2ι4036N38 S
EXAMPLE 6
Preparation ofFILQNIQGQLVGGGYA.ISPRTLVAG -NH2 (SEQ ID NO : 8).
The peptide was synthesized in amide form, from corresponding starting materials according to the general description of synthesis. The purity was determined by HPLC analysis and the structure was confirmed by amino acid analysis and mass spectrometry (LDI-MS).
Purity (HPLC): more than 97 % (single impurity less than 1%) Molecular weight (free base): 2572.0
EXAMPLE 7 - REFERENCE EXAMPLE
Preparation of a nativ p24 sequence GATPQDLNTMLNTVGGHQAA- NH2 (SEQ ID NO : 10). The peptide was synthesized in amide form, from the corresponding starting materials according to the general description of synthesis. The purity was determined by HPLC analysis and the structure was confirmed by amino acid analysis and mass spectrometry (LDI-MS). Purity (HPLC) : 98% Molecular weight (free base) : 1995.2 Molecular formula : C82Hi35θ29N2 S
EXAMPLE 8
Preparation ofYAIPQALNTLLNTVGGHQAA-NH2 (SEQ ID NO : 11). The peptide was synthesized in amide form, from the corresponding starting materials according to the general description of synthesis. The purity was determined by HPLC analysis and the structure was confirmed by amino acid analysis and mass spectrometry (LDI-MS). Purity (HPLC) : 98 % Molecular weight (free base) : 2051.4 Molecular formula : C91Hι 027N27
EXAMPLE 9
Preparation ofFAIPQALNTLLNTVGGGGHQAACG-NH2 (SEQ ID NO : 12). The peptide is synthesized in amide form, from the corresponding starting materials according to the general description of synthesis. The purity is determined by HPLC analysis and the structures is confirmed by amino acid analysis and mass spectrometry (LDI-MS).
EXAMPLE 10 - REFERENCE EXAMPLE Preparation of a nativ p24 sequence GSDIAGTTSTLQEQIGWMT- NH2 (SEQ ID NO : 13). The peptide was synthesized in amide form, from the corresponding starting materials according to the general description of synthesis. The purity was determined by HPLC analysis and the structure was confirmed by amino acid analysis and mass spectrometry (LDI-MS). Purity (HPLC) : 90%
Molecular weight (free base) : 1995.2 Molecular formula : C84H-i35θ3iN23 S
EXAMPLE 11 Preparation ofW S A L AGTTS L L Q G Q L G W I T- NH2 (SEQ ID NO : 14).
The peptide was synthesized in amide form, from the corresponding starting materials according to the general description of synthesis. The purity was determined by HPLC analysis and the structure was confirmed by amino acid analysis and mass spectrometry (LDI-MS). Purity (HPLC) : more than 97% (single impurities less than 1%) Molecular weight (free base) : 2007.3 EXAMPLE 12 - REFERENCE EXAMPLE
Preparation of a nativ p17 sequence HIVWASRELERFAVNPGLLEVT- NH2 ( SEQ ID NO : 16). The peptide was synthesized in amide form, from corresponding starting materials according to the general description of synthesis. The purity was determined by HPLC analysis and the structure was confirmed by amino acid analysis and mass spectrometry (LDI-MS). Purity (HPLC) : more than 95% Molecular weight (free base) : 2436.8
EXAMPLE 13 -REFERENCE EXAMPLE
Preparation of a nativ p24 sequence PIVQNIQGQMVHQAISPRTLNAW- NH2 ( SEQ ID NO : 17). The peptide was synthesized in amide form, from corresponding starting materials according to the general description of synthesis. The purity was determined by HPLC analysis and the structure was confirmed by amino acid analysis and mass spectrometry (LDI-MS). Purity (HPLC) : approximately 93% Molecular weight (free base) : 2601.0
EXAMPLE 14 Dimerisation via disulphide bridge.
The peptide sequences are linked via an oxidation step to form a dipeptide wherein the cysteine residues form a disulphide bridge. The bridge can for instance be formed by oxidation with l2 as follows ;
Equal amounts of the peptides are dissolved in acetic acid/methanol (1:4) and 0,1 M l2 in methanol is added yielding a mixture of the dimer.
EXAMPLE 15
A vaccine comprising the peptides of the SEQ ID NO : 3, 6, 11 and 14 is prepared. The freeze-dried peptides are dissolved in sterile water at a final concentration of 4 mg/ml. The final salt concentration of the solution is physiological compatible. A preparation of a granulocyte-macrophage-colony stimulating factor (GM-CSF) is also prepared, according to the manufacturers directions for use, to a final concentration of 0,3 mg/ml. The two solutions are administered intracutaneously. A typical injection dose is 100 μl. EXAMPLE 16
An antigen solution or suspension is mixed with equal parts of Freund s adjuvant of Behring, complete or incomplete, and is then finely emulsified by being drawn up into, and vigorously pressed out of, an injection syringe, or with a homogenator. The emulsion should remain stable for at least 30 minutes. The antigen-adjuvant emulsions is best injected subcutaneously as a depot.
EXAMPLE 17
Immunoassay for detection of antibodies induced by HIV-1. The magnetic particle reagents are to be prepared according to the manufacturers recommended protocol. Dynal AS, is the manufacturer of the Dynabeads, which are employed. The magnetic particles coated with ligand are called Reagent 1. A peptide according to the invention is covalently coupled to the pre-activated surface of the magnetic particles. It is also possible to physically absorb the peptide to the surface of the magnetic particles. The concentration of particles in Reagent 1 is within the range from 1 mg/ml to 15 mg/ml. The particle size varies between 0,2 μm to 15 μm. The concentration of peptides is within the range from 0,01 mg/mg particle to 1 mg/mg particle. The anti human Ig Alkaline Phosphatase (AP) conjugated antibody reagent is prepared according to the recommended protocol of Dako AS. This protocol is a standard procedure in this field. This reagent is called Reagent 2.
The substrate solution phenolphtalein-monophosphate is to be prepared according to the recommended protocol of Fluka AG. This protocol is a standard procedure in this field. The substrate solution is called Reagent 3.
The washing and incubation buffer which is used is standard 0,05 M tris-base buffer with the following additional compounds; Tween 20 (0,01% to 0,1%), glycerol (0,1 % to 10%) and sodium chloride (0,2% to 0,1 %). The assay procedure comprises an incubation step wherein 1 drop of Reagent 1 is mixed with 2 drops of washing buffer in each well. After mixing, 30 μl of sample is added and the solution is incubated for 5 minutes. The magnetic particles can be trapped by a magnet and the liquid removed, before the magnet is separated. Then the wells are washed twice in 4 drops of washing solution, before incubation with Reagent 2. 1 drop of Reagent 2 is added with 2 drops of washing buffer and the solution is incubated for 5 minutes. The magnetic particles can be trapped by a magnet and the liquid removed, before the magnet is separated. Then the washing step is repeated before incubation with Reagent 3. 2 drops of Reagent 3 is added to each well and the solution is incubated for 3 minutes. The results can be read against a white background. Positive results are red (3+ = strong red) whereas negative results are clearly light yellow/brown solutions as obtained in the negative control.
The immunoassay kit could be used in detection of antibodies, induced either by HIV virus or HIV-specific peptides or proteins, for instance the peptides of the present invention.
EXAMPLE 18
Therapeutic or prophylactic vaccine
At least one of the polypeptides of the invention, selected from the group of sequences, SEQ ID NO : 1 , SEQ ID NO : 4, SEQ ID NO : 9 and SEQ ID NO : 15 can be used to form antigens and be the active principle of a prophylactic or therapeutic vaccine intended to provide protection against the human immunodeficiency virus type 1 (HIV- 1). The vaccine may include compounds having beneficial effects in protecting or stimulating the hosts immune system (human being or vertebrate animal) for instance interleukins, interferons, granulocyte macrophage growth factors, haematopoietic growth factors or similar. Preferably the vaccine composition further contain an adjuvant or vehicle, more preferably the adjuvant or vehicle is Monophosphoryl Lipid A (MPL ®) possibly with alum, Freund's adjuvant (complete or incomplete) or aluminum hydroxyd. The optimal amount of adjuvant vehicle will depend on the type(s) which is/are chosen.
The peptides of the invention might be modified by C-terminal addition of a single fatty acid such as a single palmitoyl chain to form a lipopeptide vaccine. Further the lipopeptides can be introduced into liposome membranes by the freeze-thaw method resulting in liposomes bearing the peptide ligands on their surface.
The peptide or vaccine formulation can be freeze-dried prior to storage. The freeze- dried peptides can be dissolved in sterile water to a final concentration of from 0,1 to 100 mg/ml. The vaccine may be stored preferably at low temperature, in ampoules containing one or more dosage units, ready for use. A typical dosage unit of the peptide according to the invention is within the concentration range : 0,05 μg-1mg per kg bodyweight, preferably within 0,15 μg-0 15 mg per kg body weight. Persons skilled in the art will appreciate that a suitable dose will depend on the body weight of the pasient, the type of disease, severity of condition, administration route and several other factors. When used as a therapeutic vaccine the vaccine will typically initially be administered about 12 times, through injections. Further boosters might follow and in extreme cases be administered throughout the patients life. In preparation of an injection solution the peptides are dissolved in sterile water to a final concentration of 1 mg/ml per peptide. Typically an injection volume is 100 μl to 200 μl (2 x 100 μl). The peptide is preferably co-administered with a suitable adjuvant and/or a granulocyte-macrophage growth factor, for instance Leucomax® «Shering Plough)) made within a concentration range of from 0,1 to 1 mg/ml, or according to the manufacturers recommendations. Particulary preferred is a combination therapy where the present peptides are administered together with the peptides described in the published International patent application no. PCT/N 000/00075 filed March 2, 2000 and/or the co pending Norwegian Patent Application No. 20004412. The peptides may be administered sequentially or simultaneously. Suitable administration may be intracutane, subcutane, intravenous, peroral, intramuscular, intranasal, mucosal or any other suitable route. Booster administrations may be required in order to maintain protection. For persons skilled in the art it will be understood that the vaccine compositions according to the invention are useful not only in prevention of infection, but also in treatment of infection.
No toxic effects of the peptides according to the invention, are observed when injected in mice in a dosage of 100 μg per kg body weight.
The above Examples are only meant as illustrating the invention. It must be understood that a person skilled in the art can modify the peptides, antigens and vaccines herein described without deviating from the concept and scope of this invention as set forth in the claims.

Claims

PATENT CLAIMS
1. Peptide c h a r a c t e r i z e d i n t h a t it comprises at least one amino acid sequence selected from the groups of amino acid sequences :
Xaai Xaa2Xaa3Xaa4 Xaa5 Xaaβ Xaa Gln Leu Gin Xaan Xaa-ι2 Xaa13 Xaaι4Xaaι5 Xaa^ Xaa 7 Xaa18Xaaι9 Xaa2o Xaa2ι (SEQ ID NO : 1)
wherein the amino acids of the chain could have the following meanings
Xaa n position 1 of the peptide derivate is His, Lys or Arg, Xaa n position 2 is He, Leu, Val or Met, Xaa n position 3 is lie or Val, Xaa n position 4 is Trp or Tyr, Xaa n position 5 is Ala or Leu, Xaa n position 6 is Ser, Thr, Arg or Asn, Xaa n position 7 is Arg, or Ser, Xaa n position 11 s Arg, Lys, Gly or Asn, Xaa n position 12 s Phe, Ser or Tyr Xaa n position 13 s Ala, Thr or Ser Xaa n position 14 s Val, Leu, He or Cys, Xaa n position 15 s Asn, Asp or Ser, Xaa n position 16 s Pro, Arg or Ser, Xaa n position 17 s Gly, Ser, Ala, Asp or Asn Xaa n position 18 s Leu or Phe, Xaa n position 19 s Leu or Met, Xaa n position 20 s Glu, Gly, Asp or lie, Xaa n position 21 s Thr, Ser or Ala
the peptide comprises at least six consecutive amino acids of the sequence of SEQ ID NO : 1 ,
Xaai Xaa2 Xaa3 Xaa4 Xaa5 XaaeXaa7 Gly Xaa9 Leu Val -Z- Tyr Xaaι3 Xaa-| Xaa-ι5 Xaaι6 Xaa-ι Xaa18 Xaa-|9 Xaa2o Xaa2ι Ala Xaa23 Xaa24 Xaa25 Xaa26 (SEQ ID NO : 4)
wherein the amino acids of the chain have the following meaning; Xaa in position 1 is Pro, Tyr or Phe
Xaa in position 2 is He, Val or Leu,
Xaa in position 3 is lie, Ala, Val, Met or Leu
Xaa in position 4 is Gin, Ser, Thr or Val
Xaa in position 5 is Asn, Asp or Thr
Xaa in position 6 is lie, Ala, Leu or Met
Xaa in position 7 is Gin, Glu Lys or Gly
Xaa in position 9 is Gin or lie
Xaa in position 13 s omitted
Xaa in position 14 s Ala, Ser, Asn, Val or Pro
Xaa in position 15 s He, Leu, Met or Val,
Xaa in position 16 s Ser or Thr
Xaa in position 17 s Pro or Ala,
Xaa in position 18 s Arg or Lys,
Xaa in position 19 s Thr or Ser
Xaa in position 20 s Leu or Ser
Xaa in position 21 s Asn, Phe or Val,
Xaa in position 23 s Trp, Tyr, Gly or none
Xaa in position 24 s Val, Leu, Gly or none
Xaa in position 25 s Lys, Arg, Gly or none
Xaa in position 26 s Val, Ala, Cys, Gly or none wherein the sequel ice of SEQ ID NO : 4 comprises at least six consecutive amino acids and ■ -Z- is optional and have the meaning PEG, modified PEG and/or [Gly]n, wherein n
= 1 ,2 . or 3,
Xaai AlaXaa3 Xaa4Xaa5 Ala Xaa Xaa8 Xaa9 Leu Leu Xaa-ι2 Xaa13 Xaa-ι4-Z- Xaa-ι5 Xaa-ie His Gin Xaa19 Ala Xaa2ι Xaa22 (SEQ ID NO : 9)
wherein Xaa in position 1 is Tyr, Trp, Phe or Gly Xaa in position 3 is Thr, Ala, Val, lie or Leu
Xaa in position 4 is Pro or Ser
Xaa in position 5 is Gin, His, Gly, Thr, Ser or Tyr
Xaa in position 7 is Leu, He or Val
Xaa in position 8 is Asn or Tyr Xaa in position 9 is Thr, Met, Leu or Ala Xaa in position 12 s Ser, Thr or Asn Xaa in position 13 s Thr, lie, Val or Ala Xaa in position 14 s Val or lie Xaa in position 15 s Gly or none Xaa in position 16 s Gly or none Xaa in position 19 s Ala or Gly Xaa in position 20 s Ala Xaa in position 21 s Met, Leu, Cys or none Xaa in position 22 s Gin, Glu, His, Gly or none wherein the sequence of SEQ ID NO : 9 consists of at least six consecutive amino acids and the linker -Z- is optional and have the meaning PEG, modified PEG and/or [Glyjn, wherein n = 1 ,2 or 3,
Xaai Xaa2 Ala Leu Ala Gly Xaa7Xaa8 Xaa9 Leu Xaa-n Xaa-12 Xaa-13 Xaaι4Xaa-i5Xaaι6 Xaaiy Xaais Xaa-ι9 Xaa2o Xaa2ι (SEQ ID NO : 15)
wherein the Xaa in position 1 is Trp or Tyr Xaa in position 2 is Ser or Ala Xaa in position 7 is Thr, Ala or Ser Xaa in position 8 is Ser or Thr Xaa in position 9 is Ser or Thr
Xaa in position 11 is Leu, Pro, Val or Gin Xaa in position 12 is Gin, Ala or His Xaa in position 13 s Glu or Gly Xaa in position 14 is Gin or His Xaa in position 15 is lie, Leu, Val or Met Xaa in position 16 is Gly, Ala, Gin, Thr, Asn, Arg, His or He Xaa in position 17 is Trp or Tyr Xaa in position 18 is Thr, Met, Leu or lie Xaa in position 19 is Thr or Ser Xaa in position 20 s Cys, Gly or none Xaa in position 21 s Gly or none wherein the sequence of SEQ ID NO : 15 consists of at least six consecutive amino acids, the terminal ends of the sequences may be free carboxyl- or amino groups, amides, acyls, acetyls or salts thereof, two or more of the Cys residues may form part of an interchain disulphide binding, a -S- (CH2)P-S- or a - (CH2)p-bridge wherein p = 1-8 optionally intervened by one or more hetero atoms such as O, N and S and/or the said peptide sequences are immobilized to a solid support.
2. Peptide according to claim ^characterized in that the amino acid sequence of SEQ ID NO : 1 is selected from the groups of SEQ ID NO : 2 and SEQ ID NO : 3.
3. Peptide according to claim ^characterized in that the amino acid sequence of SEQ ID NO : 4 is selected from the groups of SEQ ID NO :
5. SEQ ID NO : 6 and SEQ ID NO : 8.
4. Peptide according to claim 1, characterized in that the amino acid sequence of SEQ ID NO : 9 is selected from the groups of SEQ ID NO : 11 and SEQ ID NO: 12.
5. Peptide according to claim ^characterized in that the amino acid sequence of SEQ ID NO : 15 is SEQ ID NO : 14.
6. Antigen, characterized in that it comprises at least one peptide according to claim 1.
7. Antigen according to claim 6, characterized in that it comprises at least one peptide selected from at least one of the groups SEQ ID NO : 1 , SEQ ID NO : 4, SEQ ID NO : 9 and SEQ ID NO : 15.
8. Vaccine composition, c h a ra cte ri ze d in that it comprises an antigen according to claim 6 with a pharmaceutically acceptable diluent and optionally an adjuvant, carrier and/or vehicle and optionally additional immunostimulatory compound(s).
9. Vaccine composition according to claim 8, characterized in that it comprises at least one peptide selected from the groups of SEQ ID NO : 1 , SEQ ID NO : 4, SEQ ID NO : 9 and SEQ ID NO : 15.
10. Vaccine composition according to claim 8, characterized in that it comprises the peptides of the SEQ ID NO : 3, SEQ ID NO : 6, SEQ ID NO : 11 and SEQ ID NO : 14.
11. Vaccine composition according to the claims 8-10 characterized in t h a t the peptides are dissolved in a sterile water solution and the optional immunostimulatory compound is a granulocyte macrophage colony stimulating factor.
12. Vaccine composition according to the claims 8-11 characterized in that the composition comprises an adjuvant selected from the group Monophosphoryl Lipid A (MPL®), Freund's complete or incomplete adjuvant or aluminum hydroxyd.
13. Vaccine composition, characterized in that an antigen according to claim 6 is formulated as a lipopeptide and/or a liposome formulation.
14. A method of detecting antibodies, induced by a HIV or HlV-specific peptide(s) or protein(s), in a sample of body fluid characterized in that subjecting the said sample to an immunoassay, wherein the antigen(s) is/are selected from the peptides of the claims 1,2,3,4 and 5.
15. An immunoassay kit for the detection of antibodies, induced by a HIV or HlV- specific peptides or proteins, in a sample of body fluid, characterized in that the diagnostic antigen is a peptide of any one of the previous claims 1 to*5.
16. Antibody, characterized in that it is capable of selectively reacting with the antigen of the claims 6 and 7. SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT:
(A) NAME: Bionor Immuno AS
(B) STREET: Strømdalsjordet 4, P.O.Box 1893 Gulset
(C) CITY: 3703 Skien (E) COUNTRY: Norway
(F) POSTAL CODE (ZIP): N-3705
(G) TELEPHONE: +47 35 50 57 50 (H) TELEFAX: + 47 35 50 57 01
(i) INVENTOR:
(A) NAME : Birger Sørensen
(B) STREET : Meierlia 3
(C) CITY : 3727 Skien
(D) COUNTRY : Norway
(ii) TITLE OF INVENTION: HIV peptides, antigens, vaccine compositions, immunoassay and a method of detecting antibodies induced by HIV.
(iii) NUMBER OF SEQUENCES: 17
(iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: Windows 2000
(D) SOFTWARE: Word 7.0
(v) CURRENT APPLICATION DATA: APPLICATION NUMBER:
(2) INFORMATION FOR SEQ ID NO:1 :
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: both (ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: No (v) FRAGMENT TYPE : internal
(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 1 (D) OTHER INFORMATION: /note= " Xaa in position 1 is His, Lys or Arg ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2
(D) OTHER INFORMATION: /note= " Xaa in position 2 is lie, Leu, Val or Met ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3
(D) OTHER INFORMATION: /note= " Xaa in position 3 is He or Val
ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4
(D) OTHER INFORMATION: /note= " Xaa in position 4 is Trp or Tyr ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5
(D) OTHER INFORMATION: /note= " Xaa in position 5 is Ala or Leu ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 6
(D) OTHER INFORMATION: /note= " Xaa in position 6 is Ser, Thr, Arg or Asn
ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7
(D) OTHER INFORMATION: /notβ= " Xaa in position 7 is Arg or Ser ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1 1
(D) OTHER INFORMATION: /note= " Xaa in position 11 is Arg, Lys, Gly, or Asn ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12
(D) OTHER INFORMATION: /note= " Xaa in position 12 is Phe, Ser or Tyr
ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 13
(D) OTHER INFORMATION: /note= " Xaa in position 13 is Ala, Thr or Ser ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14
(D) OTHER INFORMATION: /note= " Xaa in position 14 is Val, Leu, lie or Cys
ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 15 (D) OTHER INFORMATION: /note= " Xaa in position 15 is Asn, Ser or Asp ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 16
(D) OTHER INFORMATION: /note= " Xaa in position 16 is Pro, Arg or Ser
ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 17
(D) OTHER INFORMATION: /note= " Xaa in position 17 is Gly, Ser, Ala, Asp or Asn ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 18
(D) OTHER INFORMATION: /note= " Xaa in position 18 is Leu or Phe ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 19
(D) OTHER INFORMATION: /note= " Xaa in position 19 is Leu or Met
ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 20
(D) OTHER INFORMATION: /note= " Xaa in position 20 is Glu, Gly, Asp or He ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 21
(D) OTHER INFORMATION: /note= " Xaa in position 21 is Thr, Ser or Ala
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1 : Xaai Xaa2Xaa3Xaa4 Xaa5 Xaa6 Xaa7 Gin Leu Gin XaanXaa 2Xaa13Xaa14Xaaι5 Xaa16 1 5 10 15
Xaaι7Xaa-ιs aa-i9 Xaa 0Xaa2-ι 20
(2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid (C) STRANDEDNESS: single
(D) TOPOLOGY: both
(ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: No
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
His Leu He Tyr Leu Thr Arg Gin Leu Gin Arg Phe Ala Leu Asn Pro Gly Leu Leu He Thr 1 5 10 15 20
(2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: both (ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: No (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
Arg Leu He Tyr Ala Thr Arg Gin Leu Gin Arg Phe Ala Val Asn Pro Gly Leu Leu He Thr 1 5 10 15 20
(2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single (D) TOPOLOGY: both
(ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: No (ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 1
(D) OTHER INFORMATION: /note= " Xaa in position 1 is Pro, Tyr or Phe (ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 2
(D) OTHER INFORMATION: /note= " Xaa in position 2 is He, Val or Leu (ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 3
(D) OTHER INFORMATION: /note= " Xaa in position 3 is He, Leu, Val, Ala or Met ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 4
(D) OTHER INFORMATION: /note= " Xaa in position 4 is Gin, Ser, Thr or Val ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 5
(D) OTHER INFORMATION: /note= " Xaa in position 5 is Asn, Asp or Thr ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 6 (D) OTHER INFORMATION: /note= " Xaa in position 6 is He, Ala, Leu or Met ' ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7
(D) OTHER INFORMATION: /note= " Xaa in position 7 is Gin, Glu, Lys or Gly ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9
(D) OTHER INFORMATION: /note= " Xaa in position 9 is Gin or He ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 13
(D) OTHER INFORMATION: /note= " Xaa in position 13 is removed ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14
(D) OTHER INFORMATION: /note= " Xaa in position 14 is Ala, Ser, Asn, Val or Pro ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 15
(D) OTHER INFORMATION: /note= " Xaa in position 15 is He, Leu, Met or Val ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 16
(D) OTHER INFORMATION: /note= " Xaa in position 16 is Ser or Thr ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 17
(D) OTHER INFORMATION: /note= " Xaa in position 17 is Pro or Ala ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 18
(D) OTHER INFORMATION: /note= " Xaa in position 18 is Arg or Lys ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 19
(D) OTHER INFORMATION: /note= " Xaa in position 19 is Thr or Ser
ix) FEATURE: (A) NAME/KEY: Modified-site
(B) LOCATION: 20 (D) OTHER INFORMATION: /note= " Xaa in position 20 is Leu or Ser ix) FEATURE: (A) NAME/KEY: Modified-site
(B) LOCATION: 21 (D) OTHER INFORMATION: /note= " Xaa in position 21 is Asn, Phe or Val ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 23 (D) OTHER INFORMATION: /note= " Xaa in position 23 is Trp, Tyr, Gly or none ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 24 (D) OTHER INFORMATION: /note= " Xaa in position 24 is Val, Leu, Gly or none ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 25 (D) OTHER INFORMATION: /note= " Xaa in position 25 is Lys, Arg, Gly or none ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 26 (D) OTHER INFORMATION: /note= " Xaa in position 26 is Val, Ala, Cys, Gly or none ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 1 1..12 (D) OTHER INFORMATION: /note= " optionally inserted a -Z- linker which is PEG, modified PEG and/or [Gly]n wherein n = 1 , 2 or 3
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
Xaai aa2 Xaa3 aa4 aaβ Xaa6 Xaa7 Gly Xaag Leu Val -Z-Tyr Xaa1 Xaa15 Xaa16 1 5 10 15
Xaaι7 Xaai8XaaιgXaa20 Xaa2ι Ala Xaa23 Xaa2 Xaa25 Xaa26 20
(2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: both (ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: No (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
Tyr lie Leu Gin Asn He Glu Gly Gin Leu Val Gly Gly Gly Tyr Ala He Ser Pro Arg Thr Leu 1 5 10 15 20
Val Ala Tyr Leu Arg Gly-NH2 25
(2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 amino acids
(B) TYPE: amino acid (C) STRANDEDNESS: single
(D) TOPOLOGY: both
(ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: No (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
Phe He Leu Gin Asn He Glu Gly Gin Leu Val Gly Gly Gly Tyr Ala He Ser Pro Arg Thr Leu 1 5 10 15 20 Val Ala Gly Gly Gly Gly -OH 25 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 amino acids (B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: both
(ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: No, nativ p24 sequence (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
Pro lie Val Gin Asn lie Glu Gly Gin Met Val His Gin Ala He Ser Pro Arg Thr Leu Asn Ala 1 5 10 15 20
Trp Val Lys Val
25 (2) INFORMATION FOR SEQ ID NO: 8
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single (D) TOPOLOGY: both
(ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: No
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8
Phe He Leu Gin Asn He Gin Gly Gin Leu Val Gly Gly Gly Tyr Ala He Ser Pro Arg Thr Leu 1 5 10 15 20 Val Ala Gly 25
(2) INFORMATION FOR SEQ ID NO: 9 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid (C) STRANDEDNESS: single
(D) TOPOLOGY: both
(ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: No ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1
(D) OTHER INFORMATION: /note= " Xaa in position 1 is Tyr, Trp, Phe or Gly ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 3
(D) OTHER INFORMATION: /note= " Xaa in position 3 is Thr, Ala, Val, lie or Leu ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 4
(D) OTHER INFORMATION: /note= " Xaa in position 4 is Pro or Ser ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 5
(D) OTHER INFORMATION: /note= " Xaa in position 5 is Gin, His, Gly, Thr, Ser or Tyr ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7
(D) OTHER INFORMATION: /note= " Xaa in position 7 is Leu, lie or Val ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8
(D) OTHER INFORMATION: /note= " Xaa in position 8 is Asn or Tyr ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9
(D) OTHER INFORMATION: /note= " Xaa in position 9 is Thr, Met, Leu or Ala ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 12
(D) OTHER INFORMATION: /note= " Xaa in position 12 is Ser, Thr or Asn ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 13
(D) OTHER INFORMATION: /note= " Xaa in position 13 is Thr, He, Val or Ala ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 14
(D) OTHER INFORMATION: /note= " Xaa in position 14 is Val or He ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 15
(D) OTHER INFORMATION: /note= " Xaa in position 15 is Gly or none ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 16
(D) OTHER INFORMATION: /note= " Xaa in position 16 is Gly or none ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 19
(D) OTHER INFORMATION: /note= " Xaa in position 19 is Ala or Gly ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 21
(D) OTHER INFORMATION: /note= " Xaa in position 21 is Met, Leu, Cys or none ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 22
(D) OTHER INFORMATION: /note= " Xaa in position 22 is Gin, Glu, His, Gly or none ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 14..15
(D) OTHER INFORMATION: /note= " optionally inserted linker -Z- which is PEG, modified PEG and/or [Gly]n wherein n = 1 , 2 or 3 ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 21 (D) OTHER INFORMATION: /note= " Cys in position 21 may form part of a disulphide- bond
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9
Xaa-i Ala Xaa3 Xaa4Xaa5Ala Xaa7Xaa8 Xaag Leu Leu Xaa12 Xaa13 Xaa14-Z- Xaaι5 1 5 10 15
Xaa16 His Gin Xaa19 Ala Xaa21 Xaa22 20
(2) INFORMATION FOR SEQ ID NO: 10
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 amino acids (B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: both
(ii) MOLECULE TYPE: peptide i) HYPOTHETICAL: No, nativ p24 sequence (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10
Gly Ala Thr Pro Gin Asp Leu Asn Thr Met Leu Asn Thr Val Gly Gly His Gin Ala Ala 1 5 10 15 20
(2) INFORMATION FOR SEQ ID NO: 11
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 amino acids (B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: both
(ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: No
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1 1 Tyr Ala lie Pro Gin Ala Leu Asn Thr Leu Leu Asn Thr Val Gly Gly His Gin Ala Ala 1 5 10 15 20
(2) INFORMATION FOR SEQ ID NO: 12 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: both
(ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: No ix) FEATURE: (A) NAME/KEY: Modified-site
(B) LOCATION: 23
(D) OTHER INFORMATION: /note= " Cys in position 23 may form part of a disulphide- bond (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12
Phe Ala lie Pro Gin Ala Leu Asn Thr Leu Leu Asn Thr Val Gly Gly Gly Gly His Gin Ala
1 5 10 15 20
Ala Cys Gly
2) INFORMATION FOR SEQ ID NO:13
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: both
(ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: No, nativ p24 sequence (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13
Gly Ser Asp He Ala Gly Thr Thr Ser Thr Leu Gin Glu Gin He Gly Trp Met Thr 1 5 10 15
(2) INFORMATION FOR SEQ ID NO: 14
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: both
(ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: No
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14 Trp Ser Ala Leu Ala Gly Thr Thr Ser Leu Leu Gin Gly Gin Leu Gly Trp He Thr 1 5 10 15
(2) INFORMATION FOR SEQ ID NO: 15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: both (ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: No ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 1
(D) OTHER INFORMATION: /note= " Xaa in position 1 is Trp, Tyr ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 2
(D) OTHER INFORMATION: /note= " Xaa in position 2 is Ser or Ala ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 7
(D) OTHER INFORMATION: /note= " Xaa in position 7 is Thr, Ala or Ser ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 8
(D) OTHER INFORMATION: /note= " Xaa in position 8 is Ser or Thr ix) FEATURE:
(A) NAME/KEY: Modified-site (B) LOCATION: 9
(D) OTHER INFORMATION: /note= " Xaa in position 9 is Ser or Thr ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 11
(D) OTHER INFORMATION: /note= " Xaa in position 11 is Leu, Pro, Val or Gin ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 12
(D) OTHER INFORMATION: /note= " Xaa in position 12 is Gin, Ala or His ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 13
(D) OTHER INFORMATION: /note= " Xaa in position 13 is Gly or Glu ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 14
(D) OTHER INFORMATION: /note= " Xaa in position 14 is Gin or His ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 15
(D) OTHER INFORMATION: /note= " Xaa in position 15 is lie, Leu, Val or Met ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 16
(D) OTHER INFORMATION: /note= " Xaa in position 16 is Gly, Ala, Gin, Thr, Asn, Arg, His or He ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 17 (D) OTHER INFORMATION: /note= " Xaa in position 17 is Trp ot Tyr ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 18 (D) OTHER INFORMATION: /note= " Xaa in position 18 is Thr, He, Leu or Met ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 19 (D) OTHER INFORMATION: /note= " Xaa in position 19 is Thr or Ser ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 20 (D) OTHER INFORMATION: /note= " Xaa in position 20 is Cys, Gly or none ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 21 (D) OTHER INFORMATION: /note= " Xaa in position 21 is Gly or none ix) FEATURE: (A) NAME/KEY: Modified-site
(B) LOCATION: 20
(D) OTHER INFORMATION: /note= " Cys in position 20 may form part of a disulphide- bond
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15
Xaai a^2 Ala Leu Ala Gly Xaa7Xaa8 Xaa9 Leu Xaa-n Xaa12 Xaa13 Xaa14Xaa15 1 5 10 15 Xaa^ Xaaι7 Xaa-is Xaa-ig Xaa20 Xaa2ι
20
2) INFORMATION FOR SEQ ID NO:16 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: both
(ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: No, nativ p17 sequence (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16
His He Val Trp Ala Ser Arg Glu Leu Glu Arg Phe Ala Val Asn Pro Gly Leu Leu Glu Thr 1 5 10 15 20 2) INFORMATION FOR SEQ ID NO:17
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 amino acids
(B) TYPE: amino acid (C) STRANDEDNESS: single
(D) TOPOLOGY: both
(ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: No, nativ p24 sequence
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17
Pro lie Val Gin Asn He Gin Gly Gin Met Val His Gin Ala He Ser Pro Arg Thr Leu Asn Ala Trp 1 5 10 15 20
AU2001282706A 2000-09-04 2001-09-03 HIV peptides from conserved in gag p17 and 924 and their application in E.G. vaccines Ceased AU2001282706B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2007202739A AU2007202739B2 (en) 2000-09-04 2007-06-13 HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NO20004413A NO314588B1 (en) 2000-09-04 2000-09-04 HIV peptides, antigens, vaccine composition, immunoassay test kits and a method for detecting antibodies induced by HIV
NO20004413 2000-09-04
PCT/NO2001/000362 WO2002020554A2 (en) 2000-09-04 2001-09-03 Hiv peptides from conserved regions in gag p17 and 924 and their application in e.g. vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2007202739A Division AU2007202739B2 (en) 2000-09-04 2007-06-13 HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV

Publications (2)

Publication Number Publication Date
AU2001282706A1 true AU2001282706A1 (en) 2002-06-13
AU2001282706B2 AU2001282706B2 (en) 2007-03-22

Family

ID=19911533

Family Applications (3)

Application Number Title Priority Date Filing Date
AU8270601A Pending AU8270601A (en) 2000-09-04 2001-09-03 Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv
AU2001282706A Ceased AU2001282706B2 (en) 2000-09-04 2001-09-03 HIV peptides from conserved in gag p17 and 924 and their application in E.G. vaccines
AU2007202739A Ceased AU2007202739B2 (en) 2000-09-04 2007-06-13 HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU8270601A Pending AU8270601A (en) 2000-09-04 2001-09-03 Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2007202739A Ceased AU2007202739B2 (en) 2000-09-04 2007-06-13 HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV

Country Status (19)

Country Link
US (2) US7009037B2 (en)
EP (2) EP1878742A3 (en)
JP (2) JP2004508381A (en)
CN (2) CN101104636A (en)
AR (2) AR033998A1 (en)
AT (1) ATE406380T1 (en)
AU (3) AU8270601A (en)
BR (1) BR0114036A (en)
CA (1) CA2421193A1 (en)
DE (1) DE60135564D1 (en)
EA (1) EA006308B1 (en)
ES (1) ES2312465T3 (en)
HU (1) HUP0303134A3 (en)
MY (1) MY136081A (en)
NO (1) NO314588B1 (en)
NZ (2) NZ535148A (en)
SK (1) SK287917B6 (en)
WO (1) WO2002020554A2 (en)
ZA (1) ZA200301740B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02007478A (en) 2000-02-04 2004-08-23 Univ Duke Human immunodeficiency virus vaccine.
DE602006005686D1 (en) * 2005-08-26 2009-04-23 Novo Nordisk As METHOD FOR MODIFYING A MACROMOLECULAR SYSTEM
FI120376B (en) * 2007-01-17 2009-09-30 Next Biomed Technologies Nbt O Process for producing a high affinity biomodified polypeptide
FI120349B (en) 2007-03-07 2009-09-30 Next Biomed Technologies Nbt O Process for producing a fusion polypeptide
EP2344143A1 (en) 2008-09-09 2011-07-20 Mukesh Harilal Shukla Bioactive composition for the treatment of the hiv/aids, method for manufacturing and using the same
US20100183558A1 (en) 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
US9910040B2 (en) 2012-07-09 2018-03-06 Sevident, Inc. Molecular nets comprising capture agents and linking agents
US9733242B2 (en) 2012-10-07 2017-08-15 Sevident, Inc. Devices for capturing analyte
FR2957933B1 (en) * 2010-03-24 2012-04-27 Seppic Sa LIVE VACCINE FOR AVIAN DISEASES
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
JP6294076B2 (en) * 2011-01-06 2018-03-14 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ Multimeric peptide
RS57397B8 (en) 2011-06-10 2020-01-31 Univ Oregon Health & Science Cmv glycoproteins and recombinant vectors
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EA201492262A1 (en) * 2012-06-06 2015-08-31 Бионор Иммуно Ас CONSTRUCTION OF PEPTIDE FRAME
ES2631608T3 (en) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Env-glycoprotein variant of HIV-1
CN105102427B (en) 2013-03-21 2018-09-07 赛诺菲-安万特德国有限公司 Synthesis of Peptide Products Containing Cyclic Imides
ES2623979T3 (en) 2013-03-21 2017-07-12 Sanofi-Aventis Deutschland Gmbh Synthesis of peptide products containing hydantoin
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US11980663B2 (en) 2015-07-08 2024-05-14 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
AU2017207906B2 (en) 2016-01-15 2021-03-11 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
US10888613B2 (en) 2016-02-08 2021-01-12 American Gene Technologies International Inc. Method of producing cells resistant to HIV infection
ES2911448T3 (en) 2016-03-09 2022-05-19 American Gene Tech Int Inc Combined Vectors and Methods for Cancer Treatment
WO2017213697A1 (en) 2016-06-08 2017-12-14 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
IL284348B2 (en) * 2016-07-08 2025-06-01 American Gene Tech Int Inc Pre-HIV vaccination and immunotherapy
WO2018017882A1 (en) 2016-07-21 2018-01-25 American Gene Technologies International Inc. Viral vectors for treating parkinson's disease
KR102737836B1 (en) 2017-04-03 2024-12-03 아메리칸 진 테크놀로지스 인터내셔널 인코포레이티드 Compositions and methods for treating phenylketonuria
US11352646B2 (en) 2018-11-05 2022-06-07 American Gene Technologies International Inc. Vector system for expressing regulatory RNA
RU2727673C1 (en) * 2019-08-09 2020-07-22 Федеральное государственное унитарное предприятие «Государственный научно-исследовательский институт особо чистых биопрепаратов» Федерального медико-биологического агентства Hiv-1 subtype a p17 protein antibodies
GB2610556A (en) * 2021-09-02 2023-03-15 113 Botanicals Ltd Extraction

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235538A (en) 1989-10-12 1992-06-25 Viral Technologies Inc Peptides immunoreactive with antibodies to hiv p17; carrier-bound peptides, vaccines, immunoassay and a method for forming antibody enriched sera
SE468168B (en) 1990-02-20 1992-11-16 Replico Medical Ab HIV-1, P24 PEPTIDES, DIAGNOSTIC ANTIGENS AND PROCEDURES FOR DIFFERENTIAL DIAGNOSTICS OF PRELIMINARY HIV-1 POSITIVE SERUM TESTS
DE4039925A1 (en) 1990-12-14 1992-06-17 Behringwerke Ag SELECTED PEPTIDES OF THE GROUP-SPECIFIC ANTIGEN (GAG) OF HUMANEM IMMUNE DEFICIENCY VIRUS (HIV), THEIR PRODUCTION AND USE
SE9101863D0 (en) * 1991-06-13 1991-06-13 Replico Medical Ab PEPTIDES, DIAGNOSTIC ANTIGEN, VACCINE COMPOSITION AND PROCEDURES FOR SELECTING HIV STARMS
US6525173B1 (en) 1997-01-02 2003-02-25 Universidade Federal De Minas Gerais Process for expression and production of recombinant protein hybrid protein (p24/p17) derived from human immunodeficiency viruses (HIV-1)
GB9703802D0 (en) 1997-02-24 1997-04-16 Kingsman Susan M Anti-hiv peptides and proteins
US5972339A (en) * 1997-11-13 1999-10-26 The General Hospital Corporation Method of eliciting anti-HIV-1 helper T cell responses
US6534482B1 (en) * 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
NO311807B1 (en) 1999-03-04 2002-01-28 Bionor Immuno As HIV peptides, antigens, vaccine preparations, immunoassay test kits and a method for detecting antibodies induced by HIV

Similar Documents

Publication Publication Date Title
AU2007202739B2 (en) HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
JP5695010B2 (en) HIV peptide, antigen, vaccine composition, immunoassay kit and method for detecting antibodies induced by HIV
AU2001282706A1 (en) HIV peptides from conserved in gag p17 and 924 and their application in E.G. vaccines
AU2004200155C1 (en) HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
AU2006235980B9 (en) HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV